导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.55% | 2179/4773 |
| 近一周 | -1.45% | 2576/5467 |
| 近一月 | -8.14% | 3744/5421 |
| 近一季 | -13.91% | 3934/5238 |
| 近半年 | -2.78% | 2457/4931 |
| 近一年 | 2.93% | 1956/4400 |
| 近两年 | 68.16% | 1042/2954 |
| 近三年 | 35.22% | 885/2253 |
| 成立以来 | 9.19% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.48% 1819/4961 |
19.79% 1277/5312 |
- - |
- - |
| 2025 | 30.32% 1332/4813 |
1.17% 1681/3635 |
0.71% 2585/4076 |
27.68% 1300/4524 |
0.17% 2157/4813 |
| 2024 | 9.80% 1448/3463 |
-1.46% 1229/2808 |
-4.70% 1543/3014 |
18.00% 1079/3129 |
-0.92% 1544/3463 |
| 2023 | -12.45% 1476/2656 |
5.89% 746/2280 |
-5.05% 1359/2385 |
-7.68% 1608/2515 |
-5.67% 1453/2655 |
| 2022 | -23.87% 1172/2207 |
-17.41% 1207/1919 |
6.57% 660/2016 |
-15.13% 1223/2113 |
1.92% 1085/2208 |
| 2021 | 3.97% 594/1822 |
-5.17% 908/1255 |
10.35% 472/1330 |
-4.26% 695/1466 |
3.77% 392/1822 |
| 2020 | 36.50% 395/1250 |
-4.35% 357/1028 |
19.40% 300/1067 |
7.29% 792/1164 |
11.40% 545/1184 |
| 2019 | 41.05% 239/1092 |
33.72% 133/754 |
-6.37% 503/804 |
2.94% 278/850 |
9.44% 227/918 |
| 2018 | -32.30% 528/834 |
- - |
- - |
- - |
-12.53% 454/691 |
| 2017 | 7.12% 323/714 |
- - |
- - |
- - |
- - |
| 2016 | -18.30% 413/605 |
- - |
- - |
- - |
- - |
| 2015 | 11.62% 155/575 |
- - |
- - |
- - |
- - |
| 2014 | 34.82% 148/237 |
- - |
- - |
- - |
- - |
| 2013 | -9.74% 150/186 |
- - |
- - |
- - |
- - |
| 2012 | 2.02% 104/140 |
- - |
- - |
- - |
- - |
| 2011 | -26.83% 80/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 申万菱信深证成份指数(LOF)A VS. 长安沪深300非周期A(740101) |